Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded up 21.6% during trading on Wednesday . The company traded as high as $4.93 and last traded at $4.83. 21,567,297 shares changed hands during mid-day trading, a decline of 7% from the average session volume of 23,082,207 shares. The stock had previously closed at $3.97.
Wall Street Analyst Weigh In
RXRX has been the subject of a number of research analyst reports. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and an average price target of $8.20.
View Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
The company has a 50 day moving average of $6.78 and a two-hundred day moving average of $6.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $2.26 billion, a PE ratio of -3.67 and a beta of 1.00.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's quarterly revenue was down 57.8% on a year-over-year basis. During the same period last year, the business earned ($0.42) EPS. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the company. Softbank Group CORP. purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $99,152,000. Novo Holdings A S bought a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $68,375,000. Vanguard Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after acquiring an additional 9,737,196 shares during the last quarter. State Street Corp boosted its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock valued at $84,815,000 after acquiring an additional 4,120,685 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $23,429,000. Institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
